The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Clinical Investigation

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1172/JCI116972PMID 8282810PMCID PMC293794
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Further studies of proximal tubular brush border membraned-glucose transport heterogeneity

  2005cited by this paper
• Stoichiometric studies of the renal outer cortical brush border membraned-glucose transporter

  2005cited by this paper
• Electrogenic properties of the cloned Na+/glucose cotransporter: I. Voltage-clamp studies

  2004cited by this paper
• Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere.

  1993cited by this paper
• Steady states, charge movements, and rates for a cloned GABA transporter expressed in Xenopus oocytes.

  1993cited by this paper
• Relaxation kinetics of the Na+/glucose cotransporter.

  1993cited by this paper
• Localization of ecto-ATPase in rat kidney and isolated renal cortical membrane vesicles.

  1992cited by this paper
• Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter.

  1992cited by this paper
• Molecular evidence for two renal Na+/glucose cotransporters.

  1992cited by this paper
• Expression of mRNA (D2) encoding a protein involved in amino acid transport in S3 proximal tubule.

  1992cited by this paper
• Primary structure and functional characterization of a high-affinity glutamate transporter

  1992cited by this paper
• Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter

  1991cited by this paper
• Differential localization of two glucose transporter iso-forms in rat kidney Thorens B, Lodish HF, Brown D. Am J Physiol 1990;259:C268–C294

  1991cited by this paper
• Glucose Transport in the Renal Proximal Tubule

  1991cited by this paper
• Sequence comparison of the sodium-D-glucose cotransport systems in rabbit renal and intestinal epithelia.

  1991cited by this paper
• Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes.

  1990cited by this paper
• Expression and characterization of the intestinal Na+/glucose cotransporter in COS-7 cells.

  1990cited by this paper
• Localization of membrane-associated carbonic anhydrase type IV in kidney epithelial cells.

  1990cited by this paper
• Sequence homologies among intestinal and renal Na+/glucose cotransporters.

  1990cited by this paper
• Differential localization of two glucose transporter isoforms in rat kidney.

  1990cited by this paper
• Assignment of the human intestinal Na+/glucose cotransporter gene (SGLT1) to the q11.2----qter region of chromosome 22.

  1989cited by this paper
• Homology of the human intestinal Na+/glucose and Escherichia coli Na+/proline cotransporters.

  1989cited by this paper
• Molecular genetics of the human Na+/glucose cotransporter

  1989cited by this paper
• Characterization of a Na+/glucose cotransporter cloned from rabbit small intestine

  1989cited by this paper
• Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

  1988cited by this paper
• Intracellular sodium in proximal tubules of diabetic rats. Role of glucose.

  1988cited by this paper
• Expression cloning and cDNA sequencing of the Na+/glucose co-transporter

  1987influential reference
• Expression of size-selected mRNA encoding the intestinal Na/glucose cotransporter in Xenopus laevis oocytes.

  1987cited by this paper
• Transport of metabolic substrates by the proximal nephron.

  1985cited by this paper
• Stoichiometry of Cotransport Systems a

  1985cited by this paper
• Kinetic analysis of mechanism of intestinal Na+-dependent sugar transport.

  1985cited by this paper
• Sodium-sugar coupling stoichiometry in chick intestinal cells.

  1984cited by this paper
• Sodium, bicarbonate, and chloride absorption by the proximal tubule.

  1983cited by this paper
• Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies.

  1982cited by this paper
• Differences in active and passive glucose transport along the proximal nephron.

  1981cited by this paper
• SV40-transformed simian cells support the replication of early SV40 mutants.

  1981cited by this paper
• Acute effects of streptozotocin diabetes on rat renal function.

  1979cited by this paper
• Sugar uptake into brush border vesicles from normal human kidney.

  1977cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Renal and intestinal hexose transport in familial glucose-galactose malabsorption.

  1970cited by this paper
• Familial renal glycosuria: a genetic reappraisal of hexose transport by kidney and intestine.

  1969cited by this paper

• Mizagliflozin ameliorates diabetes induced kidney injury by inhibitor inhibit inflammation and oxidative stress

  2025cites this paper
• Current Evidence on SGLT‐2 Inhibitors in Prediabetes: A Review of Preclinical and Clinical Data

  2025cites this paper
• SGLT2 inhibitors in the prevention of nephrolithiasis: a comprehensive review

  2025cites this paper
• Pharmacological mechanisms and clinical applications between SGLT1 and SGLT2 inhibitors in type 2 diabetes and diabetic kidney disease: An analytic review.

  2025cites this paper
• The usefulness of HbA1c measurement in diabetic mouse models using various devices

  2025cites this paper
• Diuretics: a review of the pharmacology and effects on glucose homeostasis

  2025cites this paper
• Fasting hijacks proximal tubule circadian control mechanisms to regulate glucose reabsorption via the Nrf1/Sglt2 pathway in mice

  2025cites this paper
• Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer

  2025cites this paper
• Human Glucose Transporters in Health and Selected Neurodegenerative Diseases

  2025cites this paper
• The journey of Sotagliflozin: from its status as a withdrawn candidate for the treatment of diabetes mellitus, to its repurposing as a groundbreaking drug for the management of heart failure

  2025cites this paper
• Evaluating the Complications and Risk of Urosepsis after Flexible Ureteroscopy in a Sodium-Glucose Co-transporter-2 Inhibitor Population with Heart Failure with Reduced Ejection Fraction.

  2025cites this paper
• Mechanisms of diabetic kidney disease and established and emerging treatments

  2025cites this paper
• Targeting ion homeostasis in metabolic diseases: molecular mechanisms and targeted therapies.

  2025cites this paper
• Mechanism of substrate recognition and release of human SGLT2

  2025influential citation
• Diabetes and calcific aortic valve disease: implications of glucose-lowering medication as potential therapy

  2025cites this paper
• Renal glucosuria in children

  2025cites this paper
• Contribution of metabolism-independent glucose sensing to metabolic homeostasis.

  2025cites this paper
• The effect of SGLT2 inhibitors on kidney stones; a systematic review and meta-analysis

  2024cites this paper
• A comprehensive in-vitro/in-vivo screening toolbox for the elucidation of glucose homeostasis modulating properties of plant extracts (from roots) and its bioactives

  2024cites this paper
• Changes in Body Weight in Severely Obese Patients Treated with the Anorexiant Mazindol

  2024cites this paper
• Genito Urinary Infection and Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Receiving SGLT2 Inhibitors: Evidence from a Systematic Literature Review of Landmark Randomized Clinical Trial

  2024cites this paper
• Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: lessons from preclinical studies.

  2024cites this paper
• Effect of dapagliflozin on paracetamol-induced hepatotoxicity and nephrotoxicity in type 2 diabetic albino rats

  2024cites this paper
• Current Treatment Options for Diabetic Retinal Disease

  2024cites this paper
• Interplay between the Redox System and Renal Tubular Transport

  2024cites this paper
• Handling the sugar rush: The role of the renal proximal tubule.

  2024cites this paper
• Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial

  2024cites this paper
• Molecular mechanism of renal lipid accumulation in diabetic kidney disease

  2024cites this paper
• SGLT-2 inibitori nel trattamento dell’iponatremia. Quale ruolo?

  2024cites this paper
• Knocking Out Sodium Glucose–Linked Transporter 5 Prevents Fructose-Induced Renal Oxidative Stress and Salt-Sensitive Hypertension

  2024cites this paper
• Dosing Time-Dependent Difference in the Suppressive Effect of Empagliflozin on the Development of Mechanical Pain Hypersensitivity in Diabetic Mice

  2024cites this paper
• Sugar binding of sodium–glucose cotransporters analyzed by voltage-clamp fluorometry

  2024cites this paper
• Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients

  2023cites this paper
• Current Perspective on Circadian Function of the Kidney.

  2023cites this paper
• Membrane transporters in cell physiology, cancer metabolism and drug response

  2023cites this paper
• Effect of sodium-glucose cotransporter 2 inhibitors on left atrial remodeling and prognosis in patients with type 2 diabetes and heart failure with reduced ejection fraction

  2023cites this paper
• Effect of T2DM progressing on renal glucose excretion till the TmG

  2023cites this paper
• SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus.

  2023cites this paper
• Virtual Screening of Iridoids SGLT2 Inhibitors Based on Molecular Docking and Pharmacophore Model

  2023cites this paper
• Performance of the ACMG‐AMP criteria in a large familial renal glucosuria cohort with identified SLC5A2 sequence variants

  2023cites this paper
• The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers

  2023cites this paper
• Multi-Omics Reveal Interplay between Circadian Dysfunction and Type2 Diabetes

  2023cites this paper
• Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors

  2023cites this paper
• Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome

  2023cites this paper
• Synthesis, Crystal structure, Spectral analysis, DFT calculations, Docking studies, in vitro biological activity evaluation and in silico drug-likeness prediction of a novel L-xylose derivative

  2023cites this paper
• Regulatory mechanisms of glucose absorption in the mouse proximal small intestine during fasting and feeding

  2023cites this paper
• A Diversifiable Synthetic Platform for the Discovery of New Carbasugar SGLT2 Inhibitors Using Azide-Alkyne Click Chemistry.

  2023cites this paper
• Structural insights into the mechanism of the human SGLT2–MAP17 glucose transporter

  2023cites this paper
• Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review

  2023cites this paper
• SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast

  2023cites this paper
• Transport and inhibition mechanism of the human SGLT2–MAP17 glucose transporter

  2023cites this paper
• Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism

  2022cites this paper
• Structural basis of the selective sugar transport in sodium-glucose cotransporters.

  2022cites this paper
• Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation.

  2022cites this paper
• PTEN Deletion in Adult Mice Induces Hypoinsulinemia With Concomitant Low Glucose Levels

  2022cites this paper
• Structural mechanism of SGLT1 inhibitors

  2022cites this paper
• Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass

  2022cites this paper
• Studying Kidney Diseases Using Organoid Models

  2022cites this paper
• A novel SLC5A2 heterozygous variant in a family with familial renal glucosuria

  2022cites this paper
• Dual inhibition of SGLT2 and DPP-4 promotes natriuresis and improves glomerular hemodynamic abnormalities in KK/Ta-Ins2Akita mice with progressive diabetic kidney disease.

  2022cites this paper
• Current challenges in the treatment of cardiac fibrosis: Recent insights into the sex‐specific differences of glucose‐lowering therapies on the diabetic heart: IUPHAR Review 33

  2022cites this paper
• Random-walk model of the sodium-glucose transporter SGLT2 with stochastic steps and inhibition

  2022cites this paper
• Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors

  2022cites this paper
• Novel Strategies for the Treatment of COVID-19

  2022cites this paper
• Signaling pathways in obesity: mechanisms and therapeutic interventions

  2022cites this paper
• Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria

  2022cites this paper
• Circadian Clocks of the Kidney: Function, Mechanism, and Regulation.

  2022cites this paper
• Glycaemia dynamics concepts before and after insulin.

  2022cites this paper
• Update on Pathogenesis of Glomerular Hyperfiltration in Early Diabetic Kidney Disease

  2022cites this paper
• Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction

  2022cites this paper
• Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial

  2022cites this paper
• Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions

  2022cites this paper
• IgA nephropathy: an overview of drug treatments in clinical trials

  2022cites this paper
• Comparative Study of Sodium-Dependent Glucose Co-Transporters in Kidneys of Ostrich Chickens

  2022cites this paper
• Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence

  2022cites this paper
• Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways

  2021cites this paper
• Are the Protective Effects of SGLT2 Inhibitors a "Class-Effect" or Are There Differences between Agents?

  2021cites this paper
• The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathy—A Review

  2021cites this paper
• Glucose-Lowering Medications and Cardiovascular Outcomes

  2021cites this paper
• SGLT2 inhibitors as calorie restriction-mimetics: insights on longevity pathways and age-related diseases.

  2021cites this paper
• Sodium Glucose Cotransporter Inhibitors for the Treatment of Diabetes

  2021cites this paper
• Selective SGLT2 Inhibitor’s Estimation and Validation from Galenical Form by RP-HPLC Method

  2021cites this paper
• Empagliflozin Protects against Pulmonary Ischemia/Reperfusion Injury via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent Mechanism

  2021cites this paper
• Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity

  2021cites this paper
• Expression of glucose transporters in human neurodegenerative diseases.

  2021cites this paper
• Human Glucose Transporters in Renal Glucose Homeostasis

  2021cites this paper
• Single-Nucleus RNA Sequencing Identifies New Classes of Proximal Tubular Epithelial Cells in Kidney Fibrosis

  2021cites this paper
• Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient

  2021cites this paper
• Proximal tubular epithelial insulin receptor mediates high-fat diet–induced kidney injury

  2021cites this paper
• Renal Tubular Handling of Glucose and Fructose in Health and Disease.

  2021cites this paper
• SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms

  2021cites this paper
• Small intestinal glucose and sodium absorption through calcium‐induced calcium release and store‐operated Ca2+ entry mechanisms

  2021cites this paper
• Diuretic Agents

  2021cites this paper
• Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment

  2021cites this paper
• SGLT2 Inhibitors: Physiology and Pharmacology.

  2021cites this paper
• CONTEMPORARY APPROACHES IN INSULIN ADMINISTRATION FOR THE TREATMENT OF DIABETES

  2021cites this paper
• Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease

  2021cites this paper
• Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1

  2021cites this paper
• Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice

  2021cites this paper
• Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations

  2021influential citation